Peptide therapy TikTok claims: separating signal from hype

What did @onedaycompounds actually say?

Mika, the owner of One Day Compound, introduces herself and explains why she started the company: she couldn't find a research peptide supplier testing to what she considers an adequate standard. Her core claim is that most research peptide companies test for identity, purity, and weight, while her company also tests for conformity, endotoxin, sterility, and heavy metals. She adds that all testing is done at an ISO-accredited lab in the US, and that sterility testing at such a lab takes a mandatory 14 days. The framing is competitive differentiation, not a medical claim, which matters for how we evaluate it.

To her credit, she doesn't claim peptides cure anything. She uses the phrase "research use only" consistently. That restraint is notable in a space where sellers routinely blur the line between research chemicals and therapeutic products.

Does the science back this up?

The testing parameters she describes are real and meaningful. The gap between what she claims most competitors do and what her company does reflects a genuine problem in the unregulated research peptide market.

Endotoxin contamination is not a trivial concern. Bacterial endotoxins, specifically lipopolysaccharides, can cause serious inflammatory responses even in small quantities. The FDA's guidance on endotoxin limits for injectable products exists precisely because this risk is real (FDA, 2012, Guidance for Industry: Pyrogen and Endotoxins Testing). Most over-the-counter research peptide suppliers do not publish endotoxin results, and independent audits of the space have found inconsistent purity across vendors.

Heavy metals testing matters too. Peptide synthesis involves reagents and solvents that can leave trace metal contamination. A 2020 review in the Journal of Pharmaceutical and Biomedical Analysis found that metal impurities in synthetic peptides are a documented but underreported problem in non-GMP manufacturing contexts.

Her point about ISO-accredited labs is substantively correct. ISO/IEC 17025 accreditation requires labs to follow validated methods and undergo regular external audits. That is a higher bar than a company simply sending samples to any third-party lab.

What did they get wrong (or right)?

She gets the broad strokes right, but one term deserves scrutiny. She uses the word "isoecredited," which appears to be a pronunciation of ISO-accredited. Assuming that's what she means, the claim holds. ISO/IEC 17025 is the relevant standard for testing and calibration labs, and FDA does reference ISO standards in several guidance documents, though the relationship is not always as direct as she implies. The FDA does not "put procedures in place" for ISO accreditation exactly. ISO is an independent international body. The FDA references ISO standards and requires GMP compliance separately. That's a minor conflation, not a fabrication.

The 14-day sterility test claim is accurate. USP <71>, the compendial sterility test, requires a 14-day incubation period. Any lab claiming faster results for a full sterility test is likely running a different, less comprehensive assay. She gets this right.

What she cannot fully substantiate in a TikTok video is the claim that her competitors test for fewer parameters. That may be true, but without third-party audit data on competitors, it remains an unverified competitive assertion.

What should you actually know?

If you are a researcher sourcing peptides, the testing parameters Mika describes are the right ones to ask about from any supplier. Certificate of Analysis documents should include identity confirmation (typically by HPLC and mass spectrometry), purity percentage, endotoxin levels in EU/mg, sterility results, and heavy metals panels. If a supplier cannot provide all of these from a named, ISO-accredited lab, that is a gap worth taking seriously.

It is also worth knowing what "research use only" means legally. These compounds are not approved by the FDA for human therapeutic use. That designation is not a loophole for personal use. Researchers and consumers who use these compounds on themselves are operating outside the regulatory framework that exists to verify safety and efficacy. That context doesn't invalidate the testing quality argument, but it is part of the full picture.

Finally, higher testing standards reduce contamination risk. They do not validate the biological effects of the peptides being sold. A sterile, endotoxin-free vial of an unapproved compound is safer than a contaminated one. It is not the same as a clinically proven therapeutic.